Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial.

MLA

Tapia, Milagritos D., et al. “Safety, Reactogenicity, and Immunogenicity of a Chimpanzee Adenovirus Vectored Ebola Vaccine in Children in Africa: A Randomised, Observer-Blind, Placebo-Controlled, Phase 2 Trial.” The Lancet. Infectious Diseases, vol. 20, no. 6, June 2020, pp. 719–30. EBSCOhost, https://doi.org/10.1016/S1473-3099(20)30019-0.

APA

Tapia, M. D., Sow, S. O., Mbaye, K. D., Thiongane, A., Ndiaye, B. P., Ndour, C. T., Mboup, S., Keshinro, B., Kinge, T. N., Vernet, G., Bigna, J. J., Oguche, S., Koram, K. A., Asante, K. P., Gobert, P., Hogrefe, W. R., De Ryck, I., Debois, M., Bourguignon, P., … Roman, F. (2020). Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial. The Lancet. Infectious Diseases, 20(6), 719–730. https://doi.org/10.1016/S1473-3099(20)30019-0

Chicago

Tapia, Milagritos D, Samba O Sow, Khardiata D Mbaye, Aliou Thiongane, Birahim P Ndiaye, Cheikh T Ndour, Souleymane Mboup, et al. 2020. “Safety, Reactogenicity, and Immunogenicity of a Chimpanzee Adenovirus Vectored Ebola Vaccine in Children in Africa: A Randomised, Observer-Blind, Placebo-Controlled, Phase 2 Trial.” The Lancet. Infectious Diseases 20 (6): 719–30. doi:10.1016/S1473-3099(20)30019-0.